The goal of this clinical trial is to verify whether a cell culture system can be used to evaluate the presence of a factor capable of causing proteinuria in the serum of patients with primary podocytopathies. This system will also be used to evaluate the in vitro efficacy of a combined therapy for the treatment of this disorder. Researchers will compare samples from patients with primary podocytopathies with those obtained from healthy subjects and patients with other renal disorders. Participants will be asked to visit the clinic at regular intervals for up to 36 months, and to provide blood and urine samples (and a sample of the discarded plasmapheresis effluent in case the procedure is performed).
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Enrollment
150
The only interventions in addition to standard clinical practice will be blood sampling, the collection of morning spot urine and the collection of the discarded effluent of the plasmapheresis procedure (when performed according to clinical indication).
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
Milan, Italy
RECRUITINGFondazione IRCCS Policlinico San Matteo
Pavia, Italy
RECRUITINGCo-culture system capability to distinguish recurrent podocytopathies from healthy subjects
The difference in the increase of albumin permeability in the endothelium-podocyte co-culture system after exposure to serum from patients with recurrent podocytopathies and healthy subjects will be compared.
Time frame: Baseline
In-vitro efficacy of SGLT2-inhibitors and uPAR/FPR-inhibitors on primary podocytopathies
Time frame: Baseline, 16 weeks and in case of remission/recurrence
Co-culture system capability to distinguish recurrent podocytopathies from other glomerular disorders
The difference in the increase of albumin permeability in the endothelium-podocyte co-culture system after exposure to serum from patients with recurrent podocytopathies and patients with other glomerular disorders will be compared.
Time frame: Baseline
Co-culture system reliability in case of podocytopathy remission
The difference in the increase of albumin permeability in the endothelium-podocyte co-culture system after exposure to serum from patients with active podocytopathies and podocytopathies in the remission phase will be compared.
Time frame: Baseline, 16 weeks and in case of remission/recurrence
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.